Management of recurrent vulvo-vaginal candidosis as a chronic illness.
For sporadic acute Candida vaginitis, any oral or local antifungal therapy can be used. For women with recurrent vulvo-vaginal candidosis (RVC), on the other hand, such simple approaches are insufficient, regardless of the product chosen. Instead, RVC should be managed as any other chronic disease and requires long-term, prophylactic, suppressive antifungal treatment. A regimen using individualized, decreasing doses of oral fluconazole (the ReCiDiF regimen) was proven to be highly efficient and offered great comfort to the patients. During this regimen, it is crucial that patients are carefully examined by anamnestic, clinical, microscopic and culture-proven absence of Candida. If a relapse occurs, the medication is adjusted and efforts are taken to find a possible triggering factor for the reactivation of the infection. Care has to be taken not to accumulate 'don't do's', unless the efficiency of a measure has been proven, by trying to eliminate one risk factor at a time for 2 months. Known possible triggers to be kept in mind are (1) antibiotic use, (2) use of specific contraceptives, especially combined contraceptive pills, (3) disturbed glucose metabolism, (4) the use of personal hygienic products, and (5) tight clothing or plastic panty liners. In therapy-resistant cases, non-albicans infection must be ruled out, and alternative therapies should be tried. Boric acid is proven to be efficient in most of these resistant cases, but other non-azoles like amphotericin B, flucytosine, gentian violet, and even caspofungin may have to be tried. As a final remark it has to be said that many patients feel poorly understood and inefficiently managed by many care-givers, increasing their feelings of guilt and sexual inferiority. Therefore, attention has to be given to take the disease seriously, follow strict treatment regimens, and advise precisely and based on individual evidence concerning any possible risk factors for recurrence. In case of therapy-resistant vulvo-vaginitis, reconsider your diagnosis and/or consider referral to specialized therapists.
Femicare, Clinical Research for Women, Tienen, Belgium. gilbert.donders @ femicare.net
Gilbert G G
GG
Donders
Gert
G
Bellen
Werner
W
Mendling
D000935:Antifungal Agents / Q000627:therapeutic use; D002175:Candida / Q000235:genetics / Q000302:isolation & purification; D002176:Candida albicans / Q000235:genetics / Q000302:isolation & purification; D002181:Candidiasis, Vulvovaginal / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control*; D002908:Chronic Disease; D003020:Clothing; D003271:Contraceptive Agents, Female / Q000009:adverse effects; D003937:Diagnosis, Differential; D004040:Dietary Carbohydrates / Q000009:adverse effects; D025141:Drug Resistance, Fungal; D005260:Female; D053566:Hygiene Products / Q000009:adverse effects; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007109:Immunity; D008297:Male; D012008:Recurrence; D012463:Saliva / Q000382:microbiology; D012725:Sexual Behavior; D012749:Sexually Transmitted Diseases; D014621:Vagina / Q000737:chemistry / Q000382:microbiology; D014844:Vulva / Q000382:microbiology
D000935:Antifungal Agents; D003271:Contraceptive Agents, Female; D004040:Dietary Carbohydrates; D053566:Hygiene Products